Fracción gamma del proteinograma y agudizaciones de la enfermedad pulmonar obstructiva crónica

Boixeda, Ramón; Capdevila, J.A.; Vicente, Vanessa; Palomera, Elísabet; Juanola, Jordi; Albiach, Laia; Rex, Ainhoa; Almirall, Jordi

doi:10.1016/j.medcli.2016.12.042

Cited by 6 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with COPD have lower immunoglobulin G (IgG) levels than patients with other lung diseases independent of oral steroid use and age [ 15 ]. Moreover, lower baseline serum IgG or gammaglobulin levels are correlated with higher rates of AECOPD [ 16 , 17 ], but recurrent AECOPD still occur despite having normal baseline serum IgG as well [ 16 ]. There is no evidence of a threshold level of gammaglobulin or IgG to predict recurrent AECOPD risk, it rather appears to be a continuous, or linear relationship that extends into the “normal” range of immunoglublin G levels.…”

Section: Introductionmentioning

confidence: 99%

Study protocol: a randomized, double-blind, parallel, two-arm, placebo control trial investigating the feasibility and safety of immunoglobulin treatment in COPD patients for prevention of frequent recurrent exacerbations

Cowan

Mulpuru

Aaron

et al. 2018

Pilot Feasibility Stud

View full text Add to dashboard Cite

BackgroundChronic obstructive pulmonary disease (COPD) is a chronic progressive inflammatory disease of the airways, associated with frailty, disability, co-morbidity, and mortality. Individuals with COPD experience increased risk and rates of acute exacerbation as their lung disease worsens. Current treatments to prevent acute exacerbation of COPD (AECOPD) are only modestly effective. New therapies are needed to improve the quality of life and clinical outcomes for individuals living with COPD and especially for those prone to frequent recurrent AECOPD. Recent research has suggested an association of gammaglobulin or immunoglobulin G levels with AECOPD and a favorable effect of an immunoglobulin treatment on the frequency of recurrent AECOPD, healthcare provider visits, treatments, and hospitalizations. However, control trials are required to confirm this apparent association and therapeutic effect. This study aims to assess if intravenous immunoglobulin (IVIG) therapy is feasible, safe, tolerable, and potentially effective in reducing the frequency of recurrent AECOPD.Methods/designAdult COPD patients at The Ottawa Hospital (TOH) will be recruited to partake in a randomized double-blind, parallel, two-arm, placebo control trial. Eligible patients will be administered either IVIG or normal saline following 1:1 randomization and every 4 weeks for 1 year. The primary outcome of feasibility will be determined by recruitment, patient adherence, safety and tolerance, success of the follow-up procedures, and outcome measurement. The safety and tolerability will be assessed through adverse events, adherence, and study withdrawals. Efficacy trends will be investigated by assessing incidence rates of AECOPD, improvement in quality of life, and healthcare services use and cost.DiscussionThe study results will inform larger studies designed to confirm a clinically significant therapeutic effect in identifiable populations which would be a major advance in the care of COPD patients.Trial registration numberClinicalTrial.gov, NCT03018652 and NCT02690038.Electronic supplementary materialThe online version of this article (10.1186/s40814-018-0327-z) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

Study protocol: a randomized, double-blind, parallel, two-arm, placebo control trial investigating the feasibility and safety of immunoglobulin treatment in COPD patients for prevention of frequent recurrent exacerbations

Cowan

Mulpuru

Aaron

et al. 2018

Pilot Feasibility Stud

View full text Add to dashboard Cite

show abstract

Serum protein profile analysis in lysosomal storage disorders patients

Frutos

García-González

García-Rodríguez

et al. 2020

Clinica Chimica Acta

View full text Add to dashboard Cite

Primary immune deficiency diseases as unrecognized causes of chronic respiratory disease

Berger

Geng

Cameron

et al. 2017

Respiratory Medicine

View full text Add to dashboard Cite

Detection of PIDD as a potentially treatable underlying contributor to recurrent/acute exacerbations and morbidity of COPD, and provision of immunoglobulin (Ig) G replacement therapy, when appropriate, may decrease the progression of COPD. Decreasing the severity and rate of exacerbations and admissions should improve the quality of life and longevity of an important subset of patients with COPD, while decreasing costs. Major steps toward achieving these goals include developing a high index of suspicion, more frequent use and appropriate interpretation of screening tests such as quantitative immunoglobulins and vaccine responses, and prompt institution of IgG replacement therapy when antibody deficiency has been diagnosed.

show abstract

Fracción gamma del proteinograma y agudizaciones de la enfermedad pulmonar obstructiva crónica

Cited by 6 publications

References 19 publications

Study protocol: a randomized, double-blind, parallel, two-arm, placebo control trial investigating the feasibility and safety of immunoglobulin treatment in COPD patients for prevention of frequent recurrent exacerbations

Study protocol: a randomized, double-blind, parallel, two-arm, placebo control trial investigating the feasibility and safety of immunoglobulin treatment in COPD patients for prevention of frequent recurrent exacerbations

Serum protein profile analysis in lysosomal storage disorders patients

Primary immune deficiency diseases as unrecognized causes of chronic respiratory disease

Contact Info

Product

Resources

About